Mechanism of Action: Key Advances in Hematology Oncology

← Back to Supplement

Introduction

Lisa Raedler, PhD, RPh

As evidenced by the 2013 annual meetings of the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO), and the European Hematology Association (EHA), the pace at which scientific knowledge is influencing cancer drug development is astounding. Breakthroughs in our collective understanding of the underlying biology of solid and liquid tumors have revolutionized cancer treatment compared with as few as 5 years ago. Today, the “traditional” success stories of personalized cancer medicine—chronic myeloid leukemia and HER2-positive breast cancer—are being joined by reports of impressive gains in overall survival for patients with multiple myeloma, chronic lymphocytic leukemia, melanoma, lung cancer, and advanced prostate cancer. This special issue is designed to give practicing oncologists, nurses, pharmacists, and other cancer care providers a concise update on 3 promising pathways in cancer drug development: BCL-2 inhibition, JAK inhibition, and BRAF inhibition. Each of these sections reviews the biologic rationale for targeting that pathway as well as the current development status of drug therapies in that group, as reported during the AACR, ASCO, and EHA meetings. A final section on other key presentations rounds out the meetings coverage. There are drugs approved by the US Food and Drug Administration that affect JAK and BRAF; this focused update may provide additional insight on relevant clinical applications. Other novel agents are not yet available for standard use in oncology offices and clinics, but clinical trials of promising treatments may be actively recruiting patients.
Financial Toxicity, Web Exclusives - January 11, 2019

Addressing Financial Toxicity Through Systematic Change

Although the cost of care can have severe effects on patients with cancer and their families, oncologists rarely address financial toxicity, according to Hanna K. Sanoff, MD, MPH, Medical Director, University of North Carolina (UNC) NC Cancer Hospital Clinics.

FDA Approvals, News & Updates, Web Exclusives - February 5, 2020

Recap of FDA Drug Approvals in 2019

According to the FDA’s “Center for Drug Evaluation and Research (CDER) Annual Report: New Drug Therapy Approvals 2019,” the agency approved 48 novel drugs in 2019. Although this number does not approach the record of 59 approvals in 2018, it far surpasses the mere 22 approvals that occurred in 2016.